A financial model for an impact investment fund for the development of antibacterial treatments and diagnostics
Tool
1 June 2020
| Publication
Overview
This financial model was prepared as part of an overall project on setting up an impact investment fund to foster development of new antibacterial treatments. It can be used by any company, private or public investor to model cost, and risk of antibiotic development. It may also assist public entities and decision makers in calculating the possible amount and assessing the impact of instruments such as market entry rewards or milestone prizes to pull more investment into antibiotic research.The model is not meant to provide advice on individual investment decisions.
WHO would welcome any feedback. Please send any comments to: antibacterialpipeline@who.int.
Access the user guide:
Related documents:
Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline Antibacterial agents in preclinical development
WHO Team
Antimicrobial Resistance Division (AMR),
Global Coordination and Partnership (GCP)